Nanotechnology Driven Cancer Chemoradiation: Exploiting the Full Potential of Radiotherapy with a Unique Combination of Gold Nanoparticles and Bleomycin

• Published in: Pharmaceutics Vol. 14; no. 2; p. 233
• Main Authors: Han, Ocean, Bromma, Kyle, Palmerley, Nicholas, Bido, Ariadne T, Monica, Mesa, Alhussan, Abdulaziz, Howard, Perry L, Brolo, Alexandre G, Beckham, Wayne, Alexander, Abraham S, Chithrani, Devika B
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 20-01-2022; MDPI
• Subjects: Biocompatibility; bleomycin; Cancer therapies; Cell cycle; cell proliferation; Clinical trials; DNA damage; Drug delivery systems; Drug dosages; Gold; gold nanoparticles; Iodine; Nanomaterials; Nanoparticles; Nanotechnology; Peptides; Polyethylene glycol; Radiation therapy; radiotherapy; tumor cells; Tumor necrosis factor-TNF; Tumors; radiotherapy; bleomycin; tumor cells; cell proliferation; gold nanoparticles; DNA damage
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics14020233

One of the major issues in current radiotherapy (RT) is the associated normal tissue toxicity. Enhancement of the RT effect with novel radiosensitizers can address this need. In this study, gold nanoparticles (GNPs) and bleomycin (BLM) were used as a unique combination of radiosensitizers. GNPs offer a two-fold promise as a delivery vehicle for BLM and as a radiosensitizing agent. In this study, GNPs were functionalized and complexed with BLM using a gold-thiol bond (denoted GNP-BLM). Our results show that there was a 40% and 10% decrease in cell growth with GNP-BLM vs. free BLM for the MIA PaCa-2 and PC-3 cell lines, respectively. Testing the GNP-BLM platform with RT showed an 84% and 13% reduction in cell growth in MIA PaCa-2 cells treated with GNP-BLM and GNPs, respectively. Similar results were seen with PC-3 cells. The efficacy of this approach was verified by mapping DNA double-strand breaks (DSBs) as well. Therefore, this proposed incorporation of nanomedicine with RT is promising in achieving a significantly higher therapeutic ratio which is necessary to make a paradigm change to the current clinical approach.